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ABSTRACT
Objectives: Patients with cancer frequently require
unplanned admission to the intensive care unit (ICU).
Our objectives were to assess hospital and 180-day
mortality in patients with a non-haematological
malignancy and unplanned ICU admission and to
identify which factors present on admission were the
best predictors of mortality.
Design: Retrospective review of all patients with a
diagnosis of solid tumours following unplanned
admission to the ICU between 1 August 2008 and 31
July 2012.
Setting: Single centre tertiary care hospital in London
(UK).
Participants: 300 adult patients with non-
haematological solid tumours requiring unplanned
admission to the ICU.
Interventions: None.
Primary and secondary outcomes: Hospital and
180-day survival.
Results: 300 patients were admitted to the ICU
(median age 66.5 years; 61.7% men). Survival to
hospital discharge and 180 days were 69% and 47.8%,
respectively. Greater number of failed organ systems
on admission was associated with significantly worse
hospital survival (p<0.001) but not with 180-day
survival (p=0.24). In multivariate analysis, predictors of
hospital mortality were the presence of metastases (OR
1.97, 95% CI 1.08 to 3.59), Acute Physiology and
Chronic Health Evaluation II (APACHE II) Score (OR
1.07, 95% CI 1.01 to 1.13) and a Glasgow Coma Scale
Score <7 on admission to ICU (OR 5.21, 95% CI 1.65
to 16.43). Predictors of worse 180-day survival were
the presence of metastases (OR 2.82, 95% CI 1.57 to
5.06), APACHE II Score (OR 1.07, 95% CI 1.01 to
1.13) and sepsis (OR 1.92, 95% CI 1.09 to 3.38).
Conclusions: Short-term and medium-term survival
in patients with solid tumours admitted to ICU is better
than previously reported, suggesting that the presence
of cancer alone should not be a barrier to ICU
admission.
INTRODUCTION
Advances in the ﬁeld of oncology have led to
a substantial improvement in survival rates in
patients with cancer but also an increase in
the number of patients requiring admission
to the intensive care unit (ICU). A recent
study showed that around one in seven
patients admitted to general ICUs in Europe
had a malignancy, the majority being solid
tumours.1 The most common reasons for
ICU admission include postoperative routine
care, complications of the underlying
disease, side effects of cancer treatment and
medical or surgical problems not directly
related to malignancy.2 Cancer registry data
from West Scotland conﬁrmed that between
2000 and 2009, 1 in 20 patients with a non-
haematological cancer experienced a critical
illness requiring ICU admission within
2 years of cancer diagnosis.3 ICU mortality
was greatest among unplanned medical
admissions (41.7%). In contrast, ICU mortal-
ity was lowest (0.6%) in patients who were
elective surgical admissions that did not
require organ support.
Strengths and limitations of this study
▪ With 300 individual patients with solid tumours
following unplanned admission to the intensive
care unit (ICU), our study is one of the largest
available.
▪ Survival rates up to 180 days following ICU
admission were reported in 98% of our cohort
(with only 2% of patients lost to follow-up).
▪ The analysis focussed on relevant risk factors
which were present on admission to ICU in
order to aid future decision-making.
▪ Only routinely available data were retrospectively
collected.
▪ Information related to performance status pread-
mission to ICU and quality of life after discharge
from ICU were not available.
▪ All patients were admitted to the ICU in a hos-
pital with a tertiary cancer service, thereby
potentially limiting the generalisability of our
findings.
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Historically, the presence of malignant disease has
been a common reason for refusal of admission to ICU,
even in the absence of a decision to limit life-sustaining
therapies.4 Predicting outcome is difﬁcult in clinical
practice, especially since traditional physiological scores
do not perform well in this patient group.5–8 In a pro-
spective study that evaluated the outcome of critically ill
patients with cancer considered for ICU admission, 20%
of patients who were not admitted because they were
considered to be ‘too well for ICU’ died in hospital and
of the patients considered to be ‘too sick’ to beneﬁt
from ICU admission, 26% were alive on day 30 and 17%
on day 180.9
A systematic review including 48 papers published
between 2000 and 2014 showed that ICU mortality of
patients with solid tumours was between 4.5% and 85%,
while hospital mortality was reported in less studies and
ranged from 4.6% to 76.8%.10 The studies varied in
patient populations, primary malignancies, type of crit-
ical care setting (specialised oncological ICU vs general
ICU) and duration of follow-up. Some studies only
included unplanned admissions, whereas others com-
prised both patients admitted as medical emergencies
and after elective surgery. The difference in outcome
among these groups has been clearly demonstrated.11
The majority of studies (35/48) included ICU mortality
rates. Hospital mortality was reported in 31/48 studies
but outcome beyond 3 months after discharge from hos-
pital was assessed in only 8 studies. This is particularly
relevant since not all patients with cancer who leave hos-
pital alive actually return home. Sharma et al12 high-
lighted that 43% of patients with lung cancer discharged
alive from hospital were transferred to another institu-
tion, including nursing home. To offer life-sustaining
therapies to patients with cancer who have an acceptable
prognosis and to avoid unnecessary suffering in those
who are approaching the end of their life, more long-
term outcome data beyond discharge from hospital and
better understanding of prognostic factors in this patient
population are needed.13
The main objective of this study was to determine the
outcome of patients with solid tumours with unplanned
admission to a general ICU of a large teaching hospital
with particular focus on hospital and 180-day outcome.
We also aimed to identify factors present on admission
to ICU and routinely available to the treating clinicians
which were predictors of survival up to 180 days.
METHODS
Setting
Guy’s & St Thomas’ NHS Foundation Trust is a tertiary
referral centre for oncology, serving the populations
of South-East London and South-East England—UK.
Oncology inpatient and outpatient services are based
at the Guy’s Hospital site where critical care support is
provided in a 13-bed multidisciplinary ICU by
consultant-led multidisciplinary ICU team. The Guy’s
Hospital site does not have an Emergency Department,
and referrals to the ICU are made predominantly by
inpatient teams caring for patients on the medical and
surgical wards, as well as from the chemotherapy
day-unit or from other hospitals within the region. All
admissions to the ICU are discussed and approved by
the ICU consultant in charge. The ICU operates a
‘closed’ model where decisions regarding care are made
by the ICU consultant in close collaboration with the
consultant-led oncology team who are available on a
24-hour basis. The ICU has a fully computerised elec-
tronic patient record system where all medical entries,
physiological observations and laboratory data are
recorded at time of generation. Data entries related to
the presence of sepsis are mandatory ﬁelds. Full multior-
gan support including haemodynamic, renal and
advanced respiratory support can be provided at all
times.
Study design and data collection
We retrospectively screened the records of all admissions
to the ICU between 1 August 2008 and 31 July 2012 and
identiﬁed adult patients (18 years or older) with a diag-
nosis of non-haematological malignancy admitted as an
emergency. Planned admissions following elective
surgery were not included.
Following review of the literature and identiﬁcation of
the most common risk factors in patients with cancer, we
screened the patients’ computerised electronic medical
notes and laboratory records and collected the following
data: demographics, site of primary tumour, presence of
metastases, reason for admission to ICU, number of
previous ICU admissions, presence of sepsis (≥2 criteria
for Systemic Inﬂammatory Response Syndrome and
proven or suspected infection14), neutropenia (white
cell count <1.0×109/L),15 thrombocytopenia (platelet
count <20×109/L), Acute Physiology and Chronic
Health Evaluation (APACHE) II16 and Sequential Organ
Failure Assessment (SOFA) Score17 on admission to ICU
(with greater scores representing a greater degree of
physiological derangement and more severe illness),
presence of a ‘Do Not Attempt Cardio Pulmonary
Resuscitation’ (DNACPR) order and presence of signiﬁ-
cant comorbidities (excluding those directly relating to
cancer). Organ failure on admission to ICU was deﬁned
as follows: neurological failure was deﬁned by a Glasgow
Coma Score (GCS) <7/15;15 respiratory failure was
deﬁned as the need for mechanical ventilatory support
with differentiation between non-invasive ventilation
(NIV) via a face-mask versus mechanical ventilation via
an endotracheal tube; circulatory failure was deﬁned as
the need for a continuous infusion of any vasopressor or
inotropic drug; renal failure was deﬁned as the need for
renal replacement therapy (RRT) and haematological
failure was deﬁned as neutropenia (white cell count
<1.0×109/L),15 thrombocytopenia (platelet count
<20×109/L) or anaemia (haematocrit <0.2). Decisions to
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initiate organ support were made by the ICU team on a
patient by patient basis and were not protocolised.
The main outcomes were survival to hospital discharge
and to 180 days following ICU admission. Every effort
was made to determine 180-day outcome. When patients
were no longer being followed up by the oncology team
at our hospital and a date of death was not recorded in
the electronic patient record, the patient’s general prac-
titioner was contacted for further details. If the general
practitioner had not been in contact with the patient
and was unable to conﬁrm whether they were still alive,
we elected not to contact the patient or next of kin dir-
ectly to avoid any unnecessary distress. These patients
were not included in the 180-day outcome analysis.
Where patients had >1 admission to the ICU, data were
collected for each admission but only exposures and
potential confounder variables from the ﬁrst admission
to analyse hospital and 180-day outcomes.
Statistical analysis
Categorical data were summarised as frequency (per-
centage), and continuous variables were summarised as
median (IQR). Survival rates at hospital discharge and
180 days were compared across groups of patients using
a χ2 or Fisher’s exact test, as appropriate. Comparisons
between survivors and non-survivors were made using a
Mann-Whitney test when the characteristics were sum-
marised using a continuous scale.
Logistic regression models were used to identify
factors known at the time of admission which were inde-
pendently associated with hospital and with 180-day sur-
vival. All variables included in the univariable analysis
were considered for inclusion with the exception of
SOFA Score to avoid collinearity resulting from the
inclusion of other variables which are components of
the SOFA Score. Variables which were independently
associated with survival were added to the multivariable
model using a forward stepwise selection procedure.
Alongside the estimated ORs for factors which were
identiﬁed as being signiﬁcantly associated with mortality,
the estimated ORs for the excluded variables were esti-
mated by adding each variable in turn to the multivari-
able model. The goodness of ﬁt of the logistic models
was assessed using the Hosmer-Lemeshow test, and the
area under the receiver operating curve (AUC) for both
models was calculated.
Ethics
The study had institutional approval. As per Governance
Arrangements for Research Ethics Committees pub-
lished by the UK Health Departments, formal review by
a Research Ethics Committee and need for individual
informed consent were not required since the research
was limited to secondary use of information previously
collected in the course of normal care and the patients
were not identiﬁable to the research team carrying out
the research.18
RESULTS
During the 4-year study period (August 2008 to July
2012), there were 3577 admissions to the ICU of which
356 (10.0%) were unplanned admissions of 300 patients
with a solid tumour. Forty-one patients had >1 admis-
sion. The median age of patients was 66.5 years, and
61.7% were men (table 1). The median SOFA and
APACHE II Scores were 4 (IQR 2–6) and 18 (IQR 14–
21), respectively. The most frequently present tumours
were lung (43%), head and neck (17.3%), renal (6.7%)
and bladder (6.3%). One-third of patients was known to
have distant metastases. The main reasons for ICU
admission were respiratory failure, sepsis, acute kidney
injury and bleeding.
Only 13 patients (4.3%) had a non-malignancy related
signiﬁcant comorbidity: cirrhosis (1.7%), severe respira-
tory disease (1%), chronic RRT (1%), ‘very severe’
(New York Heart Association grade IV) cardiovascular
disease (0.3%) and HIV infection (0.3%). Nine patients
(3%) had a DNACPR order prior to ICU admission of
whom 6 survived to ICU discharge and 1 survived to hos-
pital discharge, but no patient survived beyond 180 days
after admission to ICU.
A total of 153 patients were admitted to ICU with
respiratory failure of whom 93 patients were treated with
NIV or mechanical ventilation on admission. The
remaining 60 patients were treated with high-ﬂow
oxygen therapy. Thirty-three patients survived to ICU
discharge without needing any respiratory support, 26
deteriorated and required respiratory support at a later
stage and 1 patient died in ICU without treatment with
NIV or mechanical ventilation.
The median survival of the total cohort following ICU
admission was 156 days. ICU survival was 79.3%, and
hospital survival following ﬁrst ICU admission was
69.0%. Furthermore, 180-day outcome data were avail-
able for 293 patients (97.7%) and showed a survival rate
of 47.8%. All 7 patients with missing 180-day outcome
data had a primary lung cancer. The median ICU
length of stay was 4 days (IQR 2–8 days) for all patients.
Risk factors
Univariable analysis
Non-survivors had signiﬁcantly higher SOFA and
APACHE II Scores on admission to ICU compared to
survivors, but there was no difference in age and gender
(table 2). Patients admitted with non-neutropenic sepsis
or following in-hospital cardiac arrest had signiﬁcantly
lower than average hospital survival (69/114 and 1/6,
respectively).
The type of the cancer primary was not associated
with hospital and 180-day survival (p=0.68 and p=0.15,
respectively), but patients with metastatic disease had sig-
niﬁcantly lower hospital and 180-day survival rates (57/
100 and 31/100, respectively, p values 0.001 and <0.001,
respectively) (table 2).
As the number of failed organ systems on admission
to ICU increased, the likelihood of survival to hospital
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discharge decreased signiﬁcantly (table 2). Hospital sur-
vival among patients with no organ failure at admission
was 76.8%, falling to 72.8%, 52.8% and 50% with 1, 2
and 3 failed organ systems, respectively. No patient with
>3 failed organ systems at admission survived to hospital
discharge. This difference was no longer signiﬁcant by
180 days. Likewise, the need for any type of organ
support (vasopressors/inotropes, RRT or ventilatory
support) on admission to ICU was associated with worse
outcomes in hospital, but only RRT was still a signiﬁcant
risk factor of death at 180 days (table 2).
Multivariable analysis
Multivariate analysis showed that the presence of metas-
tases, a GCS <7 and a higher APACHE II Score on
admission to ICU were independent risk factors for hos-
pital mortality (table 3). The AUC was 0.72. Age, male
gender, presence of neutropenia and thrombocytopenia
and need for organ support on admission to ICU (RRT,
inotropes, respiratory support) were not independently
associated with higher hospital mortality.
Metastatic disease, a higher APACHE II Score and the
presence of sepsis were independent risk factors for
180-day mortality (table 3). The AUC was 0.67. There
was no evidence of a lack of goodness of ﬁt for
the models for hospital survival (p=0.157) or 180-day
survival (p=0.252).
DISCUSSION
This retrospective analysis showed that patients with
cancer with unplanned admission to the ICU had a hos-
pital survival of 69% and a 180-day survival rate of 48%.
Presence of metastases and a higher APACHE II Score
on admission to ICU were independent risk factors for
reduced chances of survival. Need for organ support on
admission to ICU was not predictive of long-term
mortality.
There are not many studies in the literature to
compare our 180-day outcome data with since most
studies only report ICU and/or hospital outcome.
However, the survival rates in our cohort compare
favourably with other published series. Soares et al19 ana-
lysed the data of 772 critically ill patients with cancer of
whom 83% had a solid tumour. Their 6-month survival
was comparable to ours at 46%. Studies focussing on
patients with lung cancer admitted to ICU found
6-month mortality rates of 13–51.8%.20–23 Using data
from a large lung cancer registry (49 373 patients admit-
ted to an ICU in the USA between 1992 and 2007),
Slatore et al24 reported 6-month survival rates of 34.6%.
For comparison, 180-day survival in patients with lung
cancer in our cohort was 48.8%.
When caring for patients with cancer, the challenge
for ICU clinicians and oncologists is to identify those
who are likely to beneﬁt from admission to ICU and to
Table 1 Demographics and baseline data
Parameter
Patients with solid
tumours (n=300)
Age, median (IQR) 66.5 (58–73.5)
Male gender, n (%) 185 (61.7)
Type of malignancy
Lung cancer, n (%) 128 (42.7)
Head and neck cancer, n (%) 52 (17.3)
Renal cancer, n (%) 20 (6.7)
Bladder cancer, n (%) 19 (6.3)
Oesophageal cancer, n (%) 18 (6.0)
Colorectal cancer, n (%) 14 (4.7)
Prostate cancer, n (%) 9 (3.0)
Breast cancer, n (%) 8 (2.7)
Other, n (%) 32 (10.6)
Metastatic disease, n (%) 100 (33.3)
Main reasons for first admission to ICU*
Respiratory failure, n (%) 153 (51)
Non-neutropenic sepsis, n (%) 114 (38)
Neutropenic sepsis, n (%) 12 (4)
Acute kidney injury, n (%) 27 (9)
Bleeding, n (%) 22 (7.3)
Postcardiac arrest, n (%) 16 (5.3)
Cardiac emergency, n (%) 6 (2)
Other, n (%) 36 (11.9)
>1 ICU admission, n (%) 41 (13.7)
Severity of illness on admission to ICU
SOFA Score, median (IQR) 4 (2–6)
APACHE II Score, median (IQR) 18 (14–21)
Confirmed or suspected sepsis,
n (%)
201 (67)
Neutropenia, n (%) 17 (5.7)
Thrombocytopenia, n (%) 7 (2.3)
GCS <7, n (%) 23 (7.7)
Number of failed organ systems on admission to ICU
0 OF, n (%) 112 (37.3)
1 OF, n (%) 125 (41.7)
2 OF, n (%) 36 (12)
3 OF, n (%) 22 (7.3)
>3 OF, n (%) 5 (1.7)
Need for organ support on admission to ICU
Treatment with vasopressors/
inotropes, n (%)
59 (19.7)
RRT 24 (8)
Respiratory support with
non-invasive ventilation, n (%)
79 (26.3)
Respiratory support with
mechanical ventilation, n (%)
54 (18)
Outcome
Hospital survival following first
ICU admission (%)
69
180-day survival following first
ICU admission (%)†
47.8
Days in ICU, median (IQR) 4 (2–8)
*A proportion of patients had more than one reason for admission
to ICU.
†Data not available for seven patients.
APACHE, Acute Physiology and Chronic Health Evaluation; ICU,
intensive care unit; OF, failed organ systems; RRT, renal
replacement therapy; SOFA, sequential organ failure assessment.
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avoid prolonged suffering with futile treatments and
unrealistic expectations in those who are approaching
the end of their life and have low probabilities of a
meaningful survival. Favourable outcomes are commonly
observed among patients with cancer admitted to the
ICU for postoperative care, administration of chemo-
therapy or immunomodulatory agents and management
of tumour lysis syndrome.11 25 Our data show that the
probability of leaving hospital alive was also greater in
patients without established organ failure on admission
to ICU, which may be a consequence of early recogni-
tion and treatment of complications before the onset of
multiorgan dysfunction. In fact, 37.3% of patients
included in our analysis had no established organ failure
at the time of ICU admission. Interestingly, 60 patients
were admitted to ICU with respiratory failure as the
main reason for admission but did not receive NIV or
mechanical ventilation (MV) at the time of admission.
Their ICU survival was 83%. They were all treated with
high-ﬂow oxygen therapy, but 26 patients subsequently
deteriorated and required respiratory support at a later
stage. Although it is not possible to make any ﬁrm
recommendations related to optimal timing of ICU
admission, current data suggest that patients with multi-
organ failure related to delayed admission to ICU have
an increased risk of dying.26 Early admission offers an
opportunity for organ support before progression to
multiorgan failure but also provides opportunities for
high-risk diagnostic investigations which may not be
safely undertaken on the general ward.
Most studies have demonstrated an association
between short-term mortality and severity of acute
illness,27–30 greater number of failed organ systems31–37
and increased requirement for organ support including
mechanical ventilation,23 30 38–40 vasopressors36 38 39 41
and RRT.29 42 Our analysis showed that APACHE II
Score on admission to ICU was independently associated
with worse hospital and 180-day mortality. Although a
greater number of failed organ systems and the need for
organ support at ICU admission were associated with
worse hospital mortality in univariate analysis, only the
need for RRT remained an independent risk factor for
180-day mortality. This suggests that while these factors
will affect an individual’s probability of surviving the
acute illness, there is no lasting impact on risk of death
beyond this episode if the cause determining admission
to ICU is reversible. Two-thirds of patients in this study
had suspected or conﬁrmed sepsis on admission to ICU
(even if this was not their stated reason for admission).
Interestingly, they were not signiﬁcantly more likely to
die in hospital compared to patients without sepsis but
had an increased risk of dying within 180 days (OR 1.92,
95% CI 1.09 to 3.38).
The association between stage of malignant disease and
prognosis in ICU is not fully established. In our study, a
third of patients were known to have metastatic disease at
Table 2 Comparison between survivors and non-survivors (univariable analysis)
Factors on admission to ICU
Hospital
survivors
(n=207)
Hospital
non-survivors
(n=93) p Value
180-day
survivors*†
(n=140)
180-day
non-survivors*†
(n=153) p Value
Age, median (IQR) 66 (58–73) 68 (58–75) 0.62 66.5 (59–73.5) 66 (58–74) 0.60
Male gender, n (%) 129 (62) 56 (60) 0.87 88 (62.9) 97 (63.4) 0.90
SOFA Score, median (IQR) 4 (2–5) 4 (3–8) <0.001 4 (2–5) 4 (3–6) 0.048
APACHE II Score, median (IQR) 16 (13–20) 19 (16–25) <0.001 16 (12–20) 19 (15–23) 0.001
Metastatic disease, n (%) 57 (27.5) 43 (46) 0.001 31 (22) 69 (45) <0.001
Confirmed or clinically suspected
sepsis, n (%)
133 (64) 68 (73) 0.13 87 (62) 114 (74.5) 0.03
Neutropenia, n (%) 8 (3.9) 9 (9.7) 0.04 6 (4.3) 11 (7.2) 0.29
GCS <7, n (%) 8 (3.9) 15 (16.1) <0.001 8 (5.7) 15 (9.8) 0.19
Number of failed organ systems
0 OF, n (%) 86 (41.5) 26 (28) <0.001 58 (41.4) 54 (35.3) 0.24
1 OF, n (%) 91 (44) 34 (36.6) 58 (41.4) 64 (41.8)
2 OF, n (%) 19 (9.2) 17 (18.3) 18 (12.9) 18 (11.8)
3 OF, n (%) 11 (5.3) 11 (11.8) 9 (6.4) 12 (7.8)
>3 OF, n (%) 0 5 (5.4) 0 5 (3.3)
Need for organ support
Vasopressor/inotrope Rx, n (%) 32 (15.5) 27 (29) 0.006 26 (18.6) 31 (20.3) 0.83
RRT, n (%) 11 (5.3) 13 (14) 0.01 5 (3.6) 18 (11.8) 0.009
No ventilatory support, n (%) 125 (60.4) 42 (45.2) 0.043 84 (60) 82 (53.6) 0.347
Non-invasive ventilation, n (%) 50 (24.2) 29 (31.2) 30 (21.4) 44 (28.8)
Mechanical ventilation, n (%) 32 (15.5) 22 (23.7) 26 (18.6) 27 (17.6)
*Data unavailable for seven patients.
†Including patients who died in hospital.
APACHE, Acute Physiology and Chronic Health Evaluation; GCS, Glasgow Coma Score; ICU, intensive care unit; OF, organ failure; RRT,
renal replacement therapy; Rx, treatment; SOFA, sequential organ failure assessment.
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the time of ICU admission. This was associated with an
almost doubling of the risk of in hospital mortality and
approaching threefold risk of death by 180 days (OR 1.97,
95% CI 1.08 to 3.59, and OR 2.82, 95% CI 1.57 to 5.06,
respectively). Toffart et al43 evaluated the outcomes of
patients with lung cancer admitted to ICU and also found
that 90-day mortality was signiﬁcantly higher in patients
with metastatic disease (OR 1.9, 95% CI 1.08 to 3.33). It is
certainly possible that the intensity of treatment in the ICU
is inﬂuenced by the stage of the underlying cancer.
Interestingly, others reported no association between lung
cancer stage and hospital survival.21–23 44 Similarly, Azoulay
et al45 analysed the data of 120 consecutive patients with
cancer and also found that 30-day mortality was not corre-
lated with disease stage and tumour progression.
Bedside evaluation by clinicians has been deemed a
poor tool for prognostication of outcome in ICU
patients with cancer.9 In an effort to identify better
those patients likely to beneﬁt from ICU admission and
those for whom prolonged ICU care would not be
appropriate, some experts suggest a ‘trial period in ICU’
with clear goals and stopping criteria.46–48 This recom-
mendation is certainly supported by the ﬁndings of the
ICU trial, a prospective study of 188 patients with haem-
atological malignancies or solid tumours requiring
mechanical ventilation and having at least one other
organ failure.49 All patients enrolled in the study were
admitted to the ICU for full treatment followed by a
reappraisal of care on day 5. Patients who were bedrid-
den or receiving palliative care as their only cancer treat-
ment option were excluded. All patients who required
escalation of organ support after 3 days in the ICU died.
The authors showed that organ failure scores were more
accurate on day 6 than at admission and therefore con-
cluded that treatment-limitation decisions should be
considered only after 5–6 days of full ICU management.
In case of lack of improvement after this trial period,
transition to comfort or end-of-life care should be
contemplated.
With 300 individual patients, our study is larger than
many other single centre studies, despite limiting our
inclusion criteria to only those patients with unplanned
admission to the ICU. In addition, we are able to report
mortality up to 180 days following ICU admission (with
only 2% of patients lost to follow-up). We focused on
those factors which were present on admission to ICU in
order to aid future decision-making. Despite these
strengths, it is important to acknowledge some limita-
tions. First, patient identiﬁcation and data collection
were retrospective and relied on the accuracy of
the electronic records and entries made at the time.
Data collection was limited to factors which are routinely
collected as part of routine critical care. As a result, we
were not able to evaluate the impact of performance
status preadmission to ICU. We acknowledge that several
studies reported an association between worse perform-
ance status at admission and greater mortality.11 21–22 50–53
Likewise we do not have data on all potential comorbid-
ities, disease stage, details related to the oncological
treatment, response to chemotherapy prior to ICU
admission and whether treatment was given with curative
or palliative intentions. Second, we have no data on the
Table 3 Multivariable analysis of factors associated with hospital and 180-day mortality
Hospital mortality 180-day mortality*†
Factor OR 95% CI p Value OR 95% CI p Value
Variables included in the multivariable model
Presence of metastases 1.97 1.08 to 3.59 0.03 2.82 1.57 to 5.06 0.001
APACHE II Score 1.07 1.01 to 1.13 0.03 1.07 1.01 to 1.13 0.02
GCS <7 5.21 1.65 to 16.43 0.005
Confirmed or suspected sepsis 1.92 1.09 to 3.38 0.02
Variables excluded from the multivariable model
GCS <7 2.13 0.69 to 6.55 0.19
Confirmed or suspected sepsis 1.60 0.84 to 3.03 0.15
Age 1.0 0.97 to 1.02 0.79 0.99 0.97 to 1.01 0.47
Male gender 1.37 0.77 to 2.44 0.28 1.47 0.86 to 2.51 0.16
Thrombocytopenia 0.87 0.09 to 8.13 0.91 4.39 0.38 to 50.59 0.24
Neutropenia 1.28 0.32 to 5.05 0.72 0.60 0.16 to 2.28 0.45
Need for vasopressor/inotropic support 0.86 0.37 to 1.99 0.72 0.55 0.24 to 1.25 0.15
Need for RRT 1.93 0.72 to 5.15 0.19 2.62 0.84 to 8.18 0.097
No ventilation 1 1
Need for NIV 1.51 0.79 to 2.86 0.21 1.48 0.80 to 2.75 0.21
Need for MV 1.15 0.47 to 2.84 0.76 1.24 0.53 to 2.87 0.62
Variables included in the final multivariable model were selected using a forward selection procedure. ORs for variables that were not included
were estimated by adding each of the variables to the multivariable model in turn.
*Data unavailable for seven patients.
†Including patients who died in hospital.
APACHE, Acute Physiology and Chronic Health Evaluation; GCS, Glasgow Coma Score; ICU, intensive care unit; MV, mechanical ventilation;
NIV, non-invasive ventilation; RRT, renal replacement therapy; SOFA, sequential organ failure assessment.
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outcome of patients who were referred for ICU admis-
sion but declined, either on the basis of being too well
or having such a poor prognosis that ICU care was
deemed to be futile. Similarly, we have no outcome data
for patients with cancer who became critically unwell on
cancer ward but were not referred to the ICU team (In
a recent study of patients with lung cancer developing
new organ failure, only 35.0% were referred for ICU
admission by the treating team54). Third, the proportion
of patients admitted with each cancer type reﬂects the
range of tertiary services based at our hospital and the
data may not be generalisable to general ICUs in hospi-
tals without a tertiary cancer service. Fourth, patients
admitted to our ICU were less sick with lower APACHE
II and SOFA Scores on day of admission compared to
other similar studies in the literature,28 29 43 48 which
may reﬂect differences in admission policy and bed
availability. The Guy’s Hospital site has no separate high-
dependency unit, and 37.3% of patients in our study did
not require organ support at time of admission, rather
they were admitted for enhanced monitoring. This dif-
ference in severity of illness is likely to at least in part
explain the differences in observed mortality between
our study and previous reports. Fifth, we analysed the
data of patients with solid tumours but did not make
comparisons with other patient cohorts or all-comers.
Sixth, while we had 180-day survival data for 98% of
patients, we were not able to collect data on functional
status or quality of life postdischarge in survivors.
Similarly, we do not have data on the type of anticancer
therapies survivors received after ICU discharge. We
were also unable to determine how many patients were
discharged from ICU and hospital on a purely palliative
pathway. Finally, we did not collect the causes of death
and do not know how many patients died after a clinical
decision to withdraw life-sustaining therapies.
Our analysis adds to a growing number of studies that
report improved outcomes in patients with cancer admitted
to ICU. The majority of patients admitted to our ICU were
discharged from hospital alive after a relatively short intensive
care admission, and nearly half of patients were still alive
180 days after admission. Patients with organ failure requir-
ing vasopressor or ventilatory support on admission had
similar long-term outcomes to patients without organ failure.
In conclusion, short-term and medium-term survival
in patients with solid tumours admitted to ICU is better
than previously reported. Predictors of hospital mortality
were the presence of metastases, a higher APACHE II
Score and a GCS <7 on admission to ICU and risk
factors for 180-day mortality were the presence of metas-
tases, a higher APACHE II Score and sepsis on admis-
sion to ICU. The presence of cancer per se should not
be a reason for refusal of ICU admission. Instead, the
decision to admit critically ill patients with cancer to
the ICU should be based on the probability of surviving
the acute illness. More research and guidance is neces-
sary to decide which patients with cancer to admit to the
ICU for intensive life-sustaining therapies and when to
shift focus of care towards palliation and symptom
control.
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